Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 Therapy for Pediatric Acute Myeloid Leukemia

Pediatric Blood and Cancer

Volumn 57, Issue 3, 2011, Pages 398-405

  Lange, Beverly J ^a   Yang, Richard K ^b   Gan, Jacek ^b   Hank, Jaquelyn A ^b   Sievers, Eric L ^c   Alonzo, Todd A ^d,e   Gerbing, Robert B ^e   Sondel, Paul M ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Acute myeloid leukemia; Interleukin 2; Soluble interleukin 2 receptor alpha

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; IDARUBICIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD PRESSURE FLUCTUATION; CANCER CHEMOTHERAPY; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFANT; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEWBORN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; INFANT; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; SOLUBILITY; SURVIVAL ANALYSIS;

EID: 79960170607     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22966     Document Type: Article

References (35)

1. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy. Immunol Rev 1997; 157: 61-721.
2. Ruggeri L, Capanni M, Mancusi A, et al. The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol 2005; 203-206.
3. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 11: 24371-24383.
4. Waldman TA. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
5. McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 115: 2298-2305.
6. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: An overview. Oncology 2009; 23: 488-496.
7. Ringdén O, Karlsson H, Olsson R, et al. The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147: 614-633.
8. Toren A, Ackerstein A, Slavin S, et al. Role of interleukin-2 in human hematological malignancies. Med Oncol 1995; 12: 177-186.
9. Kuhn DJ, Dou QP. The role of interleukin-2 receptor alpha in cancer. Front Biosci 2005; 10: 1462-1474.
10. Murakami S. Soluble interleukin-2 receptor in cancer. Front Biosci 2004; 9: 3085-3090.
11. Bogner MP, Voss SD, Bechhofer R, et al. Serum CD25 levels during interleukin-2 therapy: Dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother 1992; 11: 111-118.
12. Bien E, Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: A review. Biomarkers 2008; 13: 1-26.
13. Higuchi CM, Thompson JA, Petersen FB, et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 71: 2561-2568.
14. Foa R, Meloni G, Guarini A, et al. Interleukin 2 (IL-2) in the management of acute myeloid leukemia: Clinical and biological findings. Leukemia 1992; 6: 115S-116S.
15. Meloni G, Foà R, Tosti S, et al. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: A pilot study. Leukemia 1993; 6: 780-785.
16. Benyunes MC, Massumoto C, York A, et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159-163.
17. Fefer A, Benyunes MC, Massumoto C, et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1993; 2041-2045.
18. Bergmann L, Heil G, Kolbe K, et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 1995; 16: 271-279.
19. Meloni G, Trisolini SM, Capria S, et al. How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia 2002; 16: 2016-2018.
20. Stein AS, O'Donnell MR, Slovak ML, et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J Clin Oncol 2003; 21: 615-623.
21. Stone RM, DeAngelo DJ, Janosova A, et al. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol 2008; 83: 1-17.
22. Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008; 26: 4934-4939.
23. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J Clin Oncol 2010; 28: 8-14.
24. Sievers EL, Lange BJ, Sondel PM, et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the Children's Cancer Group. J Clin Oncol 1998; 16: 914-919.
25. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group. Blood 2008; 111: 1044-1053.
26. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
28. Peto R, Peto J. Asymptotically efficient rank in variant test procedures. J R Stat Soc A 1972; 2: 185-206.
29. Mann HB, Whitney DR. On a test of whether one or two random variables is stochastically larger than the other. Ann Math Stat 1947; 18: 50-60.
30. Robinson N, Sanders JE, Benyunes MC, et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87: 1249-1254.
31. Hank JA, Surfus J, Gan J, et al. Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin Cancer Res 1999; 5: 281-289.
32. Wells RJ, Woods WG, Buckley JD, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Children's Cancer Group study. J Clin Oncol 1994; 12: 2367-2377.
33. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11: 1238-1243.
34. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-959.
35. Yu AL, Gilman AL, Ozkaynak MF, et al. Chimeric anti-GD2 antibody with GM-CSF, IL2 and 13-cis retinoic acid for high-risk neuroblastoma: A Children's Oncology Group (COG) phase 3 study. N Engl J Med 2010; 363: 1324-1334.